338 related articles for article (PubMed ID: 31849951)
1. Transcriptome Analysis Identifies Immune Markers Related to Visceral Leishmaniasis Establishment in the Experimental Model of BALB/c Mice.
Agallou M; Athanasiou E; Kammona O; Tastsoglou S; Hatzigeorgiou AG; Kiparissides C; Karagouni E
Front Immunol; 2019; 10():2749. PubMed ID: 31849951
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
[TBL] [Abstract][Full Text] [Related]
3. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
[TBL] [Abstract][Full Text] [Related]
4. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
[TBL] [Abstract][Full Text] [Related]
5. Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine.
Agallou M; Margaroni M; Athanasiou E; Toubanaki DK; Kontonikola K; Karidi K; Kammona O; Kiparissides C; Karagouni E
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005311. PubMed ID: 28114333
[TBL] [Abstract][Full Text] [Related]
6. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
Choudhury R; Das P; De T; Chakraborti T
Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
[TBL] [Abstract][Full Text] [Related]
7. A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum.
Pirdel L; Farajnia S
Scand J Immunol; 2017 Jul; 86(1):15-22. PubMed ID: 28426153
[TBL] [Abstract][Full Text] [Related]
8. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
[TBL] [Abstract][Full Text] [Related]
9. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
10. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
Das P; Paik D; Naskar K; Chakraborti T
Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
[TBL] [Abstract][Full Text] [Related]
11. Visceral leishmaniasis: A novel nuclear envelope protein 'nucleoporins-93 (NUP-93)' from Leishmania donovani prompts macrophage signaling for T-cell activation towards host protective immune response.
Singh MK; Jamal F; Dubey AK; Shivam P; Kumari S; Pushpanjali ; Bordoloi C; Narayan S; Das VNR; Pandey K; Das P; Singh SK
Cytokine; 2019 Jan; 113():200-215. PubMed ID: 30001865
[TBL] [Abstract][Full Text] [Related]
12. Phenotypical Characterization of Spleen Remodeling in Murine Experimental Visceral Leishmaniasis.
de Melo CVB; Hermida MD; Mesquita BR; Fontes JLM; Koning JJ; Solcà MDS; Benevides BB; Mota GBS; Freitas LAR; Mebius RE; Dos-Santos WLC
Front Immunol; 2020; 11():653. PubMed ID: 32351510
[No Abstract] [Full Text] [Related]
13. Vaccination with a CD4
Dias DS; Ribeiro PAF; Martins VT; Lage DP; Costa LE; Chávez-Fumagalli MA; Ramos FF; Santos TTO; Ludolf F; Oliveira JS; Mendes TAO; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
Transl Res; 2018 Oct; 200():18-34. PubMed ID: 29908151
[TBL] [Abstract][Full Text] [Related]
14. Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.
Santos DM; Carneiro MW; de Moura TR; Fukutani K; Clarencio J; Soto M; Espuelas S; Brodskyn C; Barral A; Barral-Netto M; de Oliveira CI
Int J Nanomedicine; 2012; 7():2115-27. PubMed ID: 22619548
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.
Chávez-Fumagalli MA; Costa MA; Oliveira DM; Ramírez L; Costa LE; Duarte MC; Martins VT; Oliveira JS; Olortegi CC; Bonay P; Alonso C; Tavares CA; Soto M; Coelho EA
Microbes Infect; 2010 Nov; 12(12-13):967-77. PubMed ID: 20601076
[TBL] [Abstract][Full Text] [Related]
17. Antigenicity, immunogenicity and protective efficacy of a conserved Leishmania hypothetical protein against visceral leishmaniasis.
Dias DS; Martins VT; Ribeiro PAF; Ramos FF; Lage DP; Tavares GSV; Mendonça DVC; Chávez-Fumagalli MA; Oliveira JS; Silva ES; Gomes DA; Rodrigues MA; Duarte MC; Galdino AS; Menezes-Souza D; Coelho EAF
Parasitology; 2018 May; 145(6):740-751. PubMed ID: 29113597
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans.
Ribeiro PAF; Dias DS; Lage DP; Costa LE; Martins VT; Tavares GSV; Mendonça DVC; Lima MP; Oliveira JS; Steiner BT; Machado-de-Ávila RA; Roatt BM; Chávez-Fumagalli MA; Menezes-Souza D; Duarte MC; Teixeira AL; Coelho EAF
Cell Immunol; 2018 Sep; 331():67-77. PubMed ID: 29871740
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
[TBL] [Abstract][Full Text] [Related]
20. Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.
Basu R; Bhaumik S; Haldar AK; Naskar K; De T; Dana SK; Walden P; Roy S
Infect Immun; 2007 Dec; 75(12):5956-66. PubMed ID: 17908806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
